Skip to content

T-Oncology Technobodies — Focus On Cancer Breakthrough Therapies

Our motivation: Taking the fear out of metastasis diagnosis

Our Brain Metastasis therapies, with a strong focus on HER2+ and TROP2, address an unmet need, will change how patients are treated, affect their prognosis and have a strong positive psychological impact.

The Challenge

There’s only limited treatment options for patients with cancer metastasis in the brain which have a wide range of side effects in existing therapies with low survival rates. Last but not least, high cost of treatments limit access to entire patient population.


HER2

Up to 50% of HER2 cancer patients will develop brain metastases.


TROP2

TROP2 cancer therapies with brain metastases are limited. Aggressive tumor behavior and poor prognosis


OTHERS

Lung, breast, and melanoma account for 67-80% of all brain metastases.

  More than 500’000 patients diagnosed annually
Overall survival is 3-14 months

T-Oncology Platform

T-Oncology addresses these challenges by providing a highly modular framework — the T-Oncology Platform with:

  • Large library of highly selective TechnoBodies and superior stability conjugates

  • Reduced side-effects through plasma half-life management

  • TechnoBodies have proven to pass brain-blood-barrier

  • Site selective payload conjugation and DAR control (DAR = 1)

  • TechnoBodies will provide very competitive total manufacturing cost

The Company

Parkstrasse 6, 6312 Steinhausen, Switzerland

T-Oncology AG is a pre-clinical stage oncology biotechnology company based in Europe that is dedicated to addressing unmet patient needs. We are at the forefront of developing and commercializing next generation, small domain antibodies breakthrough targets in the field of oncology. Our mission is to bring hope and inspiration to individuals managing cancer by delivering a proprietary smART ADC platform in collaboration with our partners. We are driven by the desire to provide options, perspective, and optimism to patients and their families during this difficult time.

Our Team

Meet the team — with renown specialists known to deliver:

Miguel Garcia-1

Dr. Miguel Garcia

Director

As a founding member of Technophage, I am thrilled to witness the launch of T-Oncology AG. By using the unique properties of single antibody domains, T-Oncology is pioneering a new approach that ensures more targeted and effective therapies with reduced side effects for patients. I am excited to see how this growing team will revolutionize oncology and improve the lives of those battling cancer.

Sofia Cortes-Real-1

Dr. Sofia Cortes-Real

Director

I am excited to witness the launch of T-Oncology AG. This innovative spin-off marks a major advancement in cancer treatment, focusing on the development of antibody-drug conjugates (ADCs) powered by harnessing the unique capabilities of single antibody domains. I look forward to seeing this dynamic team transform the field of oncology and make a real difference in the lives of those fighting cancer.

Rui Rodrigues

Dr. Rui Rodrigues

Director

Very excited to be part of this new challenging project in the biotech sciences.

Christian Weh

Christian Weh

CEO

I am excited and humbled to share the most recent progress at T-Oncology AG. A Big Thank you! to the entire team for your passion, dedication and hard work. You are truly making a difference, bringing us closer to providing hope and improved outcomes for patients.

Joao Goncalves

João Goncalves

CSO

I am honored to join T-Oncology as Chief Scientific Officer and play an essential role in advancing innovative cancer treatments. Collaborating with this passionate team, I am excited to drive scientific breakthroughs that will make a profound impact on patients' lives.

Raquel Ferreira-1

Raquel Ferreira

Head of Oncology Programs

Being part of T-Oncology presents a unique opportunity to contribute to groundbreaking medical treatments. We will have the chance to empower patients to reclaim their lives and embrace the future without fear. This mission will be realized through a dedicated and passionate team, with whom I am extremely proud to collaborate, as we work together to bring tomorrow closer.

Key Publications

Learn more about us by reading the studies behind the company

  • Andre A , Dias J Aguiar SI, Bule P, Nogueira S, Oliveira SS, Carrapiço B, Joana Carvalho, Antonio J, Braz B, Neves V. Castanho M, Cavaco M, Gois P. Gil S, Tavares L, Aires-da-Silva F.  Rabbit derived VL single-domains as promising scaffolds to generate antibody–drug conjugates. Sci Rep. 2023 March.

  • Dias JNR, Almeida A, André AS, Aguiar SI, Bule P, Nogueira S, Oliveira SS, Carrapiço B, Gil S, Tavares L, Aires-da-Silva F. Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. Sci Rep. 2022 Feb 17;12(1):2678. doi: 10.1038/s41598-022-06549-1.

  • João P. M. António, Joana Inês Carvalho, Ana S. André, Joana N. R. Dias, , Sandra I. Aguiar, Hélio Faustino, Ricardo M. R. M. Lopes, Luis F. Veiros, Gonçalo J. L. Bernardes, Frederico Aires–da-Silva, Pedro M. P. Gois. Diazaborines are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates. Angewandte Chemie. 2021 Nov 5 DOI: 10.1002/ange.202109835 2021.

  • Dias JNR, André AS, Aguiar SI, Gil S, Tavares L, Aires-da-Silva F. Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma. Front Vet Sci. 2021 Aug 26;8:621758. doi: 10.3389/fvets.2021.621758. 

  • Andre A, Moutinho I, Dias J, Aires da Silva F. In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties. Frontiers Microbiology. 022 Sep 26;13:962124. doi: 10.3389/fmicb.2022.962124.

  • Ministro JH, Oliveira SS, Oliveira JG, Cardoso M, Aires-da-Silva F, Corte-Real S, Goncalves. Synthetic antibody discovery against native antigens by CRISP/Cas-9library generation and endoplasmic reticulum screening. J.Appl Microbiol Biotechnol. 2020 Mar;104(6):2501-2512. doi: 10.1007/s00253-020-10423-3.

  • Dias JNR, Andre A, Aguiar SA, Ministro J, Peleteiro MC, Rütgen B, Gano L, Correia JDG, Oliveira S, Goncalves J, Gil S, Tavares L, Aires-da-Silva F. Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies. Plos One. (2018). Dec 28;13(12):e0208147. doi: 10.1371/journal.pone.0208147

  • Dias JNR, Aguiar SI, Pereira DM, André AS, Gano L, Correia JDG, Carrapiço B, Rütgen B, Malhó R, Peleteiro C, Goncalves J, Rodrigues CMP, Gil S, Tavares L, Aires-da-Silva F. The histone deacetylase inhibitor Panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget. (2018) Jun 19;9(47):28586-28598. doi: 10.18632/oncotarget.25580.

  • Aires da Silva F. Dias J. Aguiar J. Marques F. Andre A. Gil S. Tavares L. Novel Diagnostic and Therapeutic Immunologic Strategies to Overcome Infectious, Oncologic and Neurodegenerative Disorders. Advances in Animal Health, Medicine and Production pp 436-459. Springer.

  • Cantante C, Lourenço S, Morais M, Leandro J, Gano L, Silva N, Leandro P, Serrano M, Henriques AO, Andre A, Cunha-Santos C, Fontes C, Correia JDG, Aires da Silva F, Goncalves J. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. Journal of Biotechnology. 2017 Jul 10;253:23-33. 2017 Jul 10;253:23-33.

  • Cunha-Santos C, Figueira TN, Borrego P, Oliveira SS, Rocha C, Couto A, Cantante C, Santos-Costa Q, Azevedo-Pereira JM, Fontes CM, Taveira N, Aires-Da-Silva F, Castanho MA, Veiga AS, Goncalves J. Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. AIDS. (2016) Jul 17;30(11):1691-701. doi: 10.1097/QAD.0000000000001108.

  • Aires da Silva F, Santa-Marta F, Freitas-Vieira A, Mascarenhas P, Barahona I, Moniz-Pereira J, Goncalves J. ‘Camelizing’ Rabbit VH Single-Domain Intrabodies Against Vif Protein Strongly Neutralize HIV-1 Infectivity. J. Mol Biol. (2004), 340, 525-542. 

Key Patents

See which patents we filed to secure our intellectual property

  • Aires da Silva F, Dias J, Andre A, Aguiar S, Tavares L. Highly specific rabbit single-domain antibodies for drug delivery in immunotherapy applications. PCT/IB2022/056303 (Filing date 07/07/2022).
  • Gonçalves J & Aires da Silva F,. Engineered rabbit antibody variable domains and uses thereof. PCT/PT2008/000018; WO2008136694A9 (2008).
  • Silva F, Andre A, Dias J. Aguiar S, Oliveira S, Tavares L. Rabbit derived single-domain antibodies as promising scaffolds for the development of highly specific and potent antibody drug conjugates. PPP117461 (2021).
  • Aires da Silva, Aguiar S, Andre S, Oliveira S. Single domain antibodies for brain targeting and drug delivery across the blood-brain barrier. PPP117330 (2021).
  • Corte-Real, S., Neves, V., Oliveira, S., Canhao, P., Outeiro, T., Castanho, M., Aires da Silva, F. and Oliveira S. Antibody Molecules And Peptide Delivery Systems For Use In Alzheimer’s Disease And Related  Disorders. PCT/IB2016/050467; WO2016/120843 A1 (2016).
  • Gonçalves J. Aires da Silva F, Corte-Real S; Oliveira S, Cell-Based Methods for Coupling Protein Interactions and Binding Molecule Selection and Diversification. PCT/PT2014/000016. (2014)
  • Aires da Silva F, Corte-Real S; Gonçalves J. Dual Antigen-Binding Molecules and Uses Thereof. PCT 61/771,546, (2013).
  • Aires da Silva F, Corte-Real S; Freitas R, Lourenço S. Anti-Tumor Necrosis Factor-Alpha Agents and Uses Thereof. PCT/PT2012/000035; WO2013043070A9 (2012).
  • Aires da Silva F, Corte-Real S; Lourenço S. Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics. PCT/PT2012/000036; WO/2013/043071 (2012)

Contact Us

Curious to learn more? Get in touch with us! You’ll finde us in LinkedIn or drop us a note below: